scispace - formally typeset
Open AccessJournal ArticleDOI

CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload

Reads0
Chats0
TLDR
CYP2E1 is one of the fifty-seven cytochrome P450 genes in the human genome and is highly conserved as discussed by the authors, which has been the focus of scientific interest due to its important endogenous function in liver homeostasis.
Abstract
CYP2E1 is one of the fifty-seven cytochrome P450 genes in the human genome and is highly conserved. CYP2E1 is a unique P450 enzyme because its heme iron is constitutively in the high spin state, allowing direct reduction of, e.g., dioxygen, causing the formation of a variety of reactive oxygen species and reduction of xenobiotics to toxic products. The CYP2E1 enzyme has been the focus of scientific interest due to (i) its important endogenous function in liver homeostasis, (ii) its ability to activate procarcinogens and to convert certain drugs, e.g., paracetamol and anesthetics, to cytotoxic end products, (iii) its unique ability to effectively reduce dioxygen to radical species causing liver injury, (iv) its capability to reduce compounds, often generating radical intermediates of direct toxic or indirect immunotoxic properties and (v) its contribution to the development of alcoholic liver disease, steatosis and NASH. In this overview, we present the discovery of the enzyme and studies in humans, 3D liver systems and genetically modified mice to disclose its function and clinical relevance. Induction of the CYP2E1 enzyme either by alcohol or high-fat diet leads to increased severity of liver pathology and likelihood to develop ALD and NASH, with subsequent influence on the occurrence of hepatocellular cancer. Thus, fat-dependent induction of the enzyme might provide a link between steatosis and fibrosis in the liver. We conclude that CYP2E1 has many important physiological functions and is a key enzyme for hepatic carcinogenesis, drug toxicity and liver disease.

read more

Citations
More filters
Journal ArticleDOI

A Biomimetic Nanoparticle Exerting Protection Against Acute Liver Failure by Suppressing CYP2E1 Activity and Scavenging Excessive ROS.

TL;DR: In this article , a carrier-free and bilirubin dotted nanoparticle (B/BG@N) was developed to reduce the production of NAPQI and ROS.
References
More filters
Journal ArticleDOI

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

TL;DR: There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
Journal Article

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

TL;DR: Findings in 20 patients with nonalcoholic steatohepatitis of unknown cause found the patients were moderately obese, and many had obesity-associated diseases, such as diabetes mellitus and cholelithiasis.
Journal ArticleDOI

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

TL;DR: Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Journal ArticleDOI

Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities

TL;DR: Data indicate that peripheral insulin resistance, increased fatty acid beta oxidation, and hepatic oxidative stress are present in both fatty liver and NASH, but NASH alone is associated with mitochondrial structural defects.
Related Papers (5)